Zobrazeno 1 - 10
of 282
pro vyhledávání: '"direct acting antiviral drugs"'
Autor:
Patrik Roser, Mona Brunstein, Michael Specka, Jörg Timm, Stefan Kühnhold, Fabrizio Schifano, Udo Bonnet, Norbert Scherbaum
Publikováno v:
Harm Reduction Journal, Vol 21, Iss 1, Pp 1-10 (2024)
Abstract Background Direct acting antivirals (DAAs) as a curative treatment of hepatitis C have been available for several years and have replaced interferon-containing therapies. However, treatment rates of people who inject drugs (PWID) are declini
Externí odkaz:
https://doaj.org/article/9861bcb80e984246810b3ef275bf47ed
Autor:
Ying Wang, Yangguang Su, Kairui Zhao, Diwei Huo, Zhenshun Du, Zhiju Wang, Hongbo Xie, Lei Liu, Qing Jin, Xuekun Ren, Xiujie Chen, Denan Zhang
Publikováno v:
Heliyon, Vol 10, Iss 14, Pp e34244- (2024)
At the beginning of the ''Disease X'' outbreak, drug discovery and development are often challenged by insufficient and unbalanced data. To address this problem and maximize the information value of limited data, we propose a drug screening model, LG
Externí odkaz:
https://doaj.org/article/05119be3a5bf40ae808125db7d829789
Publikováno v:
Liver Cancer, Pp 1-13 (2024)
Background: Surveillance for hepatocellular carcinoma (HCC) has been proven to increase the proportion of tumors detected at early stages and the chance of receiving curative therapies, reducing mortality by about 30%. Summary: Current recommendation
Externí odkaz:
https://doaj.org/article/55d3e05ee80c4cee994b28771130f9f2
Autor:
Mikhail Yu. Kartashov, Kirill A. Svirin, Ajbek A. Bekbolotov, Kunduz T. Momusheva, Baarinisa M. Iskanova, Ajgul' S. Solpueva, Ulukbek T. Motorov, El'mira B. Narmatova, Ekaterina I. Krivosheina, Anastasiya V. Gladysheva, Elena V. Chub, Natal'ya M. Gashnikova
Publikováno v:
Вопросы вирусологии, Vol 68, Iss 3, Pp 265-270 (2023)
Introduction. The countries of Central Asia, including Kyrgyzstan, are characterized by high prevalence and morbidity of HCV infection. Identification of HCV genotype and mutations associated with resistance to direct-acting antiviral (DAA) plays an
Externí odkaz:
https://doaj.org/article/6a0b88aea7b9492abb856b991037b668
Publikováno v:
中西医结合护理, Vol 8, Iss 12, Pp 341-346 (2022)
Combination of peginterferon-alpha (PEG-IFN) and ribavirin (RBV) therapy is the current standard of care for chronic hepatitis C. This paper reviewed the studies of drug-related adverse reactions in hepatitis C patients who received PEG-IFN and RBV t
Externí odkaz:
https://doaj.org/article/5f343afa3ab44b96899680d001d4691b
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
Hafiza Arooba Riaz, Dur E. Nishwa, Ameer Fatima, Braira Wahid, Akhtar Ali, Babita Kumari, Muhammad Idrees
Publikováno v:
Heliyon, Vol 9, Iss 5, Pp e16169- (2023)
Introduction: Hepatitis C virus (HCV) is the second major cause of death in Pakistan. Previously, interferon-based regimens were considered highly recommended therapy for HCV patients. Since 2015, interferon-based therapy has been replaced with inter
Externí odkaz:
https://doaj.org/article/5fde9f91f27246ffa47a8fadde42dcce
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
Elsayed Ghoneem, Ahmed Saleh, Shahira Aly El-Etreby, Metwaly Ibrahim Mortada, Mayada A. Ghannam, Shaimaa El-Ashwah, Noha Eisa
Publikováno v:
Egyptian Liver Journal, Vol 11, Iss 1, Pp 1-6 (2021)
Abstract Background Hepatitis C virus (HCV) infection is a major cause of liver-related morbidity and mortality among thalassemic patients. Direct-acting antiviral agents (DAAs) are highly effective and well-tolerated by chronic HCV patients. Results
Externí odkaz:
https://doaj.org/article/d40e097a5acc48d3a251cd821a9355e8
Autor:
Asmaa M. Elbrolosy, Moamena S. Elhamouly, Emad M. Eed, Gamalat A. El Gedawy, Mai Abozeid, Naglaa S. Elabd
Publikováno v:
Egyptian Liver Journal, Vol 11, Iss 1, Pp 1-9 (2021)
Abstract Background Successful eradication of hepatitis C virus (HCV) has great impact on the prognosis of HCV-related complications and the associated mortality. The development of the new direct-acting antiviral drugs (DAAs) has revolutionized the
Externí odkaz:
https://doaj.org/article/34d15a0a9d1a42acafd3a887ab60209c